Redeye: Strax Q3 2022 - Steps in the right direction
Management continues to execute according to its action list, having divested two brands plus its licensing business in Q3. It aims to sell its Health & Wellness business in the coming two to four months. Having cut revenues and EBIT by around 7%, we have adjusted our Base Case only marginally from SEK3.1 to SEK2.9.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking.